Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Hans Gelderblom; Robin L. Jones; Jean Yves Blay; Suzanne George; Margaret von Mehren; John Zalcberg; Yoon‐Koo Kang; Albiruni Abdul Razak; Jonathan C. Trent; Steven Attia; Axel Le Cesne; Brittany L. Siontis; David Goldstein; Kjetil Boye; César Sánchez; Neeltje Steeghs; Piotr Rutkowski; Mihaela Druta; César Serrano; Neeta Somaiah; Ping Chi; B. Harrow; Claus Becker; William M. Reichmann; Matthew L. Sherman; Rodrigo Ruiz‐Soto; Michael C. Heinrich; Sebastian Bauer

doi:10.1016/j.ejca.2023.113245

Related publications

Article2022

Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.

Hans Gelderblom, Robin L. Jones, Jean Yves Blay, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, B. Harrow, Claus Becker, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich, Sebastian Bauer

Article2022

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Sebastian Bauer, Robin L. Jones, Jean Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich

Article2024

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Michael C. Heinrich, Robin L. Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, César Sánchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, César Serrano, Neeta Somaiah, Ping Chi, William M. Reichmann, Kam Sprott,

Article2021

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle, Richard S. Finn, Shukui Qin, Masafumi Ikeda, Andrew X. Zhu, Tae‐You Kim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Sohail Mulla, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Juan Liu, Chen Huang, Ho Yeong Lim, Ann‐Lii Cheng, Michel Ducreux

Article2021

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Tatsuya Yamashita, Jung‐Hwan Yoon, Lætitia Fartoux, Krzysztof Simon, Carlos López, Max W. Sung, Kalgi Mody, Tatsuroh Ohtsuka, Toshiyuki Tamai, L. Michelle Bennett, Genevieve Meier, В. В. Бредер